Literature DB >> 1338315

Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria.

M Hedberg1, L Lindqvist, K Tunér, C E Nord.   

Abstract

Three beta-lactamase inhibitors in clinical use--clavulanic acid, sulbactam and tazobactam--were investigated for their activity on beta-lactamases from Bacteroides uniformis, Clostridium butyricum and Fusobacterium nucleatum. Purification of the beta-lactamases was carried out by anion-exchange chromatography, gel filtration and FPLC. The inactivation of beta-lactamase activity was determined spectrophotometrically with nitrocefin as substrate. Various concentrations of the inhibitors were preincubated at 30 degrees C together with the enzyme for different periods of time before determination of the beta-lactamase activity. The three beta-lactamases tested were more susceptible to tazobactam than to clavulanic acid and sulbactam. Clavulanic acid and sulbactam reduced the enzyme activity of the Bacteroides uniformis beta-lactamase more effectively than the Clostridium butyricum and Fusobacterium nucleatum beta-lactamases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1338315     DOI: 10.1007/bf01967805

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  12 in total

Review 1.  Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

Review 2.  Classification of beta-lactamases: groups 1, 2a, 2b, and 2b'.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

3.  Formation of beta-lactamase in Bacteroides fragilis: cell-bound and extracellular activity.

Authors:  B Olsson; C E Nord; T Wadström
Journal:  Antimicrob Agents Chemother       Date:  1976-05       Impact factor: 5.191

Review 4.  Methodology for the study of beta-lactamases.

Authors:  K Bush; R B Sykes
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

5.  Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.

Authors:  P C Appelbaum; S K Spangler; M R Jacobs
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

Review 6.  beta-Lactamase inhibitors in perspective.

Authors:  K Bush; R B Sykes
Journal:  J Antimicrob Chemother       Date:  1983-02       Impact factor: 5.790

7.  Purification and characterization of a new beta-lactamase from Clostridium butyricum.

Authors:  T Kesado; L Lindqvist; M Hedberg; K Tunér; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

8.  Properties of novel beta-lactamase produced by Bacteroides fragilis.

Authors:  A Yotsuji; S Minami; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1983-12       Impact factor: 5.191

9.  Purification and properties of a novel beta-lactamase from Fusobacterium nucleatum.

Authors:  K Tunér; L Lindqvist; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

10.  Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate.

Authors:  C H O'Callaghan; A Morris; S M Kirby; A H Shingler
Journal:  Antimicrob Agents Chemother       Date:  1972-04       Impact factor: 5.191

View more
  2 in total

Review 1.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.